NCT03924245 - Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

February 4, 2022

Study Completion Date

February 4, 2022

Conditions

Fallopian Tube CancerFallopian Tube CarcinosarcomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaHigh Grade Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaOvarian CarcinosarcomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaPrimary Peritoneal Serous AdenocarcinomaRecurrent Endometrial CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Interventions

DRUG

Entinostat

Given by mouth

DRUG

Olaparib

Given by mouth

Trial Locations (2)

37232

Vanderbilt-Ingram Cancer Center, Nashville

66160

University of Kansas Cancer Center, Kansas City